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Abstract
Background: The purpose of this study is to discover potential biomarkers in serum for the detection of small cell
lung cancer (SCLC).
Methods: 74 serum samples including 30 from SCLC patients and 44 from healthy controls were analyzed using
ClinProt system combined with matrix-assisted laser desorption/ionization time-of-flight masss spectrometry
(MALDI-TOF-MS). ClinProt software and genetic algorithm analysis selected a panel of serum markers that most
efficiently predicted which patients had SCLC.
Results: The diagnostic pattern combined with 5 potential biomarkers could differentiate SCLC patients from
healthy persons, with a sensitivity of 90%, specificity of 97.73%. Remarkably, 88.89% of stage I/II patients were
accurately assigned to SCLC.
Conclusions: Anchorchip-time-of-flight spectrometry technology will provide a highly accurate approach for
discovering new biomarkers for the detection of SCLC.
Background
Early diagnosis appears to be the most appropriate tool
to reduce disease-related mortality. With the advent of
proteomics, the comparison of large numbers of pro-
teins in complex biological samples such as serum has
become feasible. Recently, new strategies that facilitate
proteomic analysis by magnetic beads dramatically sim-
plifying the preanalytical sample separation and coupling
with mass spectrometry (MS) have been introduced for
biomarker discovery research. The matrix-assisted laser
desorption/ionization time-of-flight masss spectrometry
(MALDI-TOF MS) profiling has been successfully used
to differentiate colorectal l [1], breast, prostate [2], and
bladder cancer from controls. Similar studies of lung
cancer have not been reported yet.
In this study, we analyzed serum samples from SCLC
patients and healthy individuals using ClinProt system.
We could find potential biomarkers in SCLC and
establishing the pattern for discriminating SCLC
patients from healthy controls.
Materials and methods
Cancer patients and controls
Serum samples including 30 SCLC patients and 44
healthy individuals were obtained from the serum banks
of the Department of Respiratory Medicine, Second
Affiliated Hospital of Medical School of Xi’an Jiaotong
University from October 2003 to May 2008. SCLC
group had a median age of 51.68 years(ranging from 33
to 71 years, 25 men and 5 women) and consisted of 9
stage I/II and 21 stage III/IV patients according to the
International Union Against Cancer (UICC)staging sys-
tem of lung cancer. Diagnoses were pathologically con-
firmed, and specimens were obtained before treatment.
The median age of the control group with no evidence
of disease was 49.0 (ranging from 44 to76 years, 28 men
and 16 women). All serum samples were separated by
centrifugation, then immediately aliquoted and stored in
a dedicated -80°C freezer. Approval for the study was
given by the Regional Ethical Committee.
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Isolation of peptides
Peptides were captured and concentrated using mag-
netic beads based weak cation exchange (MB-WCX) on
the ClinProt robotic platform (Bruker Daltonics, Biller-
ica, MA) according to the manufacturer’s specifications.
All analyses were performed in a 96-well format using
the same batch of magnetic particles. This system auto-
mates all liquid handling steps, including magnetic
separation via a robotic manipulating arm, mixing of
eluates with MALDI matrix, and deposition onto the
Bruker 384-spot MALDI target plates.
MALDI Analysis
Peptide profiles were analyzed with an Autoflex
MALDI-TOF mass spectrometer (Bruker, Billerica, MA)
as described [3]. Separate spectra were obtained for the
restricted m/z ranges, corresponding to polypeptides
with molecular mass of 800-40000 Da under specifically
optimized instrument settings. Each spectrum was the
result of 400 laser shots. Peptide samples were always
mixed with 10 μL premade a-cyano-4-hydroxycinnamic
acid (ACCA) matrix solution (Agilent), deposited onto
the stainless steel target surface in every other column
of the 384-spot layout, and allowed to dry at room tem-
perature. A weekly performance test using commercial
human reference serum (Sigma catalog number S-7023,
lot 034K8937) was done and the experiment was dupli-
cated in exactly same order. Hereafter, the entire pro-
cess of capturing and concentrating serum proteins
using magnetic beads including the generation of read-
outs of the MALDI-TOF spectra will be designated as
the protein profiling procedure.
Bioinformatics analysis
A k-nearest neighbor genetic algorithm contained in the
software suite was used to identify statistically significant
differences in protein peaks in the groups analyzed. The
peaks inputted to the model with highest accuracy were
selected as the set of potential biomarkers. After the
model was generated, a 20% leave out cross-validation
process was performed within the software. Only the
cross-validated values were used for the reported classi-
fications. The peaks were filtered to maintain a S/N of
more than three. The protein fingerprint data were ana-
lyzed by FlexAnalysis3.0. Comparisons between SCLC
group and control group were performed with the Wil-
coxon test. Statistical significance was assumed when
P was < 0.05.
Results
Peptide Profiling of SCLC patient Sera
System reproducibility was verified on the same day by
visual comparison of 13 reference samples/spectra and
the coefficient of variation (CV) of the selected peaks’
mass was always less than 30% and did not differ statis-
tically between the different sample and laser settings
(table 1). The mass accuracy was achieved by external
calibration. Using the ClinProt platform described
herein, we analyzed 74 serum samples including 30
from SCLC patients and 44 healthy individuals. The dis-
criminatory masses were clustered and selected after
noise filtering. These peaks were ranked according to
the p value of Wilcoxon rank sum test. A total of 100
distinct peptide peaks were unambiguously resolved ran-
ging from 800 to 10 000 Da between two groups. We
detected 9 peptides that showed statistically significant
differences (P < 0.000001). Both top two peaks at
1778.67 and 1865.79 Da were highly expressed in SCLC
patients, but weakly expressed in healthy individuals
(Figure 1, Figure 2).
Peptide Ion Signatures Provide Predictive Model for a
Validation Set
All detected peaks were used with a k-nearest neighbor
genetic algorithm in ClinProt system to generate a cross-
validated classification model. With the highest predictive
value, the model comprised five potential biomarkers with
m/z of 4172.21, 1211.27, 5336.83, 6333.6 and 7469.23 Da,
respectively. While the peaks with m/z 4172.21 and
6333.60 Da, were expressed higher in healthy controls
than in SCLC patients, the other three biomarkers
appeared to be expressed in an opposite way. The model
has a sensitivity of 90.00% (27/30) and a specificity of
97.73% (43/44). 88.89% (8/9) of stage I/II patients were
accurately assigned to SCLC group. The descriptive statis-
tics of these five peaks were shown in Table 2.
Discussion
SCLC is a highly aggressive and chemoresponsive dis-
ease in which the best predictor of outcome appears to
Table 1 Serum pool (n = 13) in the mass range 1000-10
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be staged at diagnosis [4]. This tumor is characterized
by a rapid doubling time, high growth fraction, and the
early development of wide-spread metastases. Currently,
no satisfactory biomarkers are available to screen for
small-cell lung cancer (SCLC).
Protein expression profiling of body fluids from
patients with cancer has recently become a valuable tool
for obtaining information on the state of protein circuits
inside tumor cells and outside the cells at the host-
tumor interface. During last years, it has been demon-
strated that the serum is a convenient protein-rich
information reservoir that may show a systemic
response to a specific disease [5]. In serum, low molecu-
lar weight proteins and peptides that are related to this
altered microenvironmental “cancerous” state can be
detected.
MS instrumentation and analysis tools have continued
to rapidly evolve and improve our ability to detect less-
abundant serum proteins. Until now, the most com-
monly used instrument was the SELDI-TOF MS. This
technology has been used successfully to discover poten-
tial serum diagnostic markers for breast [6], lung [7],
Figure 1 Representative MALDI-TOF MS serum spectra(1.7-1.9 kD). (A)Two differentially expressed proteins of m/z 1778.67 and 1865.79 Da
were screened up; (B) It showed the bar graphs, the mean values and the standard deviations of the log-normalized intensities for the SCLC
subjects (red) and the healthy individuals (green).
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bladder [8], liver [9], and gastric [10]cancers. After the
original highly intriguing report that the serum pro-
teome profile can be used for the early detection of
ovarian cancer, many researchers have applied the
SELDI-TOF MS technology to detect proteome profiles
specific for other forms of cancer and non-malignant
disease. However, SELDI-TOF MS does not allow a
direct identification of the discriminatory proteins and
the debate about the reproducibility has been particu-
larly strong [11]. The new ClinProt system providing the
optimal reproducibility is suitable for automated protein
profiling and has the capability to simultaneously iden-
tify potential biomarker proteins. The improved sensitiv-
ity and resolution allowed detection of 400 polypeptides
(0.8-15 kDa range) in a single droplet (10-50 μL) of
serum, and almost 2000 unique peptides in larger sam-
ple sets, which can then be analyzed using common
microarray data analysis software. It has been success-
fully used to identify highly sensitive and specific
potential biomarkers for the diagnosis of many cancers,
but similar studies of lung cancer have not been
reported.
There are many tumor markers detected in the sera of
patients with lung cancers. Using an array of biomarkers is
one way of acquiring a differentiated cancer diagnosis. At
present, this is usually performed by means of RIA or
ELISA. The most extensively investigated circulating pro-
tein markers include tissue polypeptide specific antigen
(TPS), neuron-specific enolase (NSE) and pro-gastrin-
releasing peptide (ProGRP). It has reported that the sensi-
tivity, specificity and accuracy of SCLC diagnosis by an
indicator of TPS and NSE were 84.4%, 87.8%, 83.6% and
79.3%, 93.7%, 88.3%, respectively, In addition, the level of
TPS and NSE in the patients’ serum with metastatic SCLC
were markedly higher than those in the patients with
SCLC without metastasis, increased with the number of
metastatic focuses [12]. The presence of SOX Group B
and/or ZIC2 AAs are frequently observed in small cell
lung carcinoma (SCLC), and were also reported to be indi-
cators of a better prognosis [13].
Here we adopted the ClinProt system to establish a
fingerprint pattern including five proteins to distinguish
SCLC patients from healthy individuals with a specificity
of 97.73% and a sensitivity of 90.00%. 88.89% SCLC
patients of the early stage were accurately diagnosed. It
is noteworthy that our pattern was helpful for the diag-
nosis of SCLC with early stage. With the highest predic-
tive value, the top two peaks (1778.67 and 1865.79 Da)
were unqualified to selected as the set of potential bio-
markers, even though they had the significant
Figure 2 Scatter plot of the top two peaks on basis of which the classification patient-control group was made: The x-axis
represented 1865.79 Da and the y-axis represented 1778.67 Da in order to observe their ability of sample distribution. The farrago
area was small and it showed that they could distinguish SCLC (red) from controls (green) effectively.
Table 2 The statistics of five candidate biomarkers for
screening SCLC(S) from healthy individuals(H)




4172.21 < 0.000001 37.06 ± 25.13 96.66 ± 33.83
6333.6 0.000523 17.14 ± 7.86 24.97 ± 6.99
1211.27 0.0538 7.28 ± 3.8 5.05 ± 3.91
5336.83 0.0548 389.28 ± 341.28 230.51 ± 99.69
7469.23 0.444 16.28 ± 8.88 14.55 ± 3.72
Du et al. Diagnostic Pathology 2010, 5:60
http://www.diagnosticpathology.org/content/5/1/60
Page 4 of 5
confidence. Among the five biomarkers, two were up-
regulated in cancer patients, and they may be oncogene
proteins. Other three were down-regulated in cancer
patients, and they may be tumor suppressor gene pro-
teins. The m/z with 5336.83 Da was lowly expressed in
SCLC patients. Freed et al [14]. also found a serum bio-
marker at 5337.62 Da with down-regulated in head and
neck squamous cell cancer (HNSCC) samples by
MALDI-TOF MS technology. Therefore, this potential
biomarker remains interesting to be further investigated.
Conclusions
In the current study, we were encouraged to find that
the combined model successfully classified all 9 stage
I/II SCLC patients from healthy individuals, which sug-
gest that our approach is useful for early SCLC detec-
tion. However, the sample size in this study is still
limited and a larger number of samples are needed to
further test our model. Nonetheless, by establishing
serum protein fingerprint patterns through MALDI-
TOF MS approach, we have provided a novel highly
sensitive and specific method for SCLC diagnosis. This
study is an initial proof for a successful evolution of the
potentially great use of discriminating protein profiles in
the detection of SCLC. Further research is needed to
confirm our current findings in larger cohorts of study
samples.
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